View Post

New study sheds light on the best drug choices for some patients with advanced breast cancer

In Clinical Studies News by Barbara Jacoby

By: Institute of Cancer Research From: medicalxpress.com Patients with metastatic breast cancer carrying a particular mutation fare better on one form of hormone therapy than another and can be identified using a blood test, according to a new study. In a combined analysis of two major Phase III clinical trials, called SoFEA and EFECT, researchers were able to show that …

View Post

Acquired ESR1 Mutations Predict Poor Benefit from Further AI Therapy in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Patients with hormone receptor (HR) positive metastatic breast cancer who acquired ESR1 mutations during prior aromatase inhibitor therapy had worse survival when treated with the aromatase inhibitor exemestane compared with fulvestrant, a combined analysis of the phase 3 SoFEA and EFECT trials found. The results were recently reported in Clinical Cancer Research. The EFECT …